ProQR to Present at Upcoming Scientific Meeting and Investor Conference Press release … A presentation titled “Therapeutic RNA editing by Axiomer ® editing oligonucleotides” by Janne Turunen, PhD, … février 06, 2018
ProQR to Webcast Virtual Analyst Event on November 18 Press release … to highlight its clinical stage pipeline programs and the Axiomer ® RNA editing platform. ProQR leadership will … novembre 11, 2021
ProQR Announces Expert Perspectives Conference Call Series Press release … pigmentosa and ProQR’s RNA oligonucleotide platform and Axiomer RNA editing approaches. Event Details Date/Time: June … juin 12, 2020
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 Press release … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called … avril 26, 2022
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release … Class I) mutations in the CFTR gene using the Company’s Axiomer ® technology platform, and provide an update on other … octobre 24, 2017
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis Press release … intends to target these mutations using its proprietary Axiomer ® technology, which has shown compelling data in … septembre 25, 2017
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Press release LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. février 27, 2019